title: Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.|Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.|Cancer Research UK Manchester Institute, Withington, Manchester, M20 4BX, UK.
authors.forename: Matthew
authors.identifier: 0000-0003-3241-5529
authors.initials: M
authors.lastname: Howell
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.|Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.
authors.forename: Adam
authors.initials: A
authors.lastname: Gibb
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.|Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.|Institute of Cancer Sciences, The University of Manchester, Manchester, M13 9PL, UK.
authors.forename: John
authors.initials: J
authors.lastname: Radford
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.|Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.|Institute of Cancer Sciences, The University of Manchester, Manchester, M13 9PL, UK.
authors.forename: Kim
authors.initials: K
authors.lastname: Linton
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006689:Hodgkin Disease / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D012008:Recurrence; D019233:Retreatment; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin; D000069461:Bendamustine Hydrochloride
keywords: Hodgkin lymphoma; allogeneic transplantation; bendamustine; brentuximab vedotin; refractory